ArticleEULAR rheumatology open2026

Canakinumab for systemic-onset juvenile idiopathic arthritis/Still's disease-effectiveness and safety data from the BiKeR registry.

Gerd Horneff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.